New hope for PMR sufferers: drug combo aims to reduce steroid use
NCT ID NCT07286214
First seen Jan 05, 2026 · Last updated May 11, 2026 · Updated 24 times
Summary
This study tests whether adding the drug sarilumab to a slow steroid taper helps adults with early polymyalgia rheumatica (PMR) achieve lasting remission. About 300 people aged 50 and older will receive either sarilumab or a placebo, along with a 52-week steroid reduction plan. The goal is to see if sarilumab can control the disease better than steroids alone, while reducing side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYMYALGIA RHEUMATICA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.